A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 18424-365

To Learn More Call
201-510-0910